

One Stop Technical Solutions of PROTAC Drugs

We have a professional technology platform and an experienced team to provide one-stop PROTAC drugs technological solutions for global customers.



With over 4300 employees, Porton Pharma Solutions, a global company with R&D and GMP-compliant manufacturing facilities across US, EU and China, provides customer-centric innovative and reliable CDMO solutions for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, etc.) from pre-clinical to commercial.



5

Regulated Markets
Approval



20+

Global Sites



1200+

R&D Chemists



2000+

Total Capacity (m³)



1000+

Global Customers



3500+

Milestone Projects

Strategies for PROTAC Molecules



More Convergent
Routes Will Be
Designed



Flow Chemistry
Acts as An Ideal
Solution for
Certain
“Dangerous”
Reactions



HTS for Metal and
Bio Catalysis
Reactions



Crystallization
Process
Development for
Both API and
Intermediates



Insoluble Drug
Enabling
Technology

Porton Pharma Solutions Ltd.

business@portonpharma.com
www.portonpharma.com

© PORTON, V1 2024


WeChat



Porton PROTAC Molecule Experience


POI Ligand

Porton has extensive experience with a range of POI ligands, including CDK4 / 6, AR, BTK etc.




Linker

Several different types of linkers have been utilized in Porton including both flexibility and rigidity.



E3 Ligase Ligand

CRBN and VHL E3 ligands have been developed for different Protac molecules.



POI Ligand



E3 Ligase Ligand

Extensive Experience in E3 Ligase Ligand CDMO Services

| E3 Ligase Ligand | Indication | Clinical Phase |
|------------------|---------------------|----------------|
| VHL | Androgenic alopecia | P2 |
| CRBN | Prostatic cancer | P1 |
| CRBN | Not disclosed | IND |
| Novel type | Not disclosed | IND+P2 |
| Novel type | Not disclosed | P1 |